Molecular Targeting of Cancer
Current medical practices in oncology are limited in providing physicians with cancer-specific information. CT and FDG-based PET/CT scans are the primary methods of imaging used in oncology today. These scans often fail to provide accurate information. Resultant images can be confusing. It is difficult to differentiate between “possible” tumor areas and normal tissue.
Enlyton recognizes that cancer imaging should enable more definitive interpretation. Our technology improves molecular imaging by providing cancer-specific images that more accurately reflect the extent of disease.